CorMedix (CRMD) shares rallied 14.8% in the last trading session to close at $5.88. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock’s 29.3% gain over the past four weeks.
Last month, the company resubmitted the new drug application for its lead product, DefenCath, an antibacterial and antifungal solution which is designed to prevent bloodstream infections related to the use of central venous catheters in patients undergoing chronic hemodialysis. This might have been driving the share price rally. Earlier this month, the company announced that it has appointed Joseph Todisco, as the new chief executive officer. This is also a positive.
This pharmaceutical and medical device company is expected to post quarterly loss of $0.22 per share in its upcoming report, which represents a year-over-year change of -15.8%. Revenues are expected to be $0.04 million, down 33.3% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For CorMedix, the consensus EPS estimate for the quarter has been revised 47.6% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on CRMD going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see
the complete list of today’s Zacks Rank #1 (Strong Buy) stocks here >>>>
CorMedix is a member of the Zacks Medical – Biomedical and Genetics industry. One other stock in the same industry, Viridian Therapeutics, Inc. (VRDN), finished the last trading session 1.2% lower at $20.19. VRDN has returned 6.7% over the past month.
Viridian Therapeutics, Inc.’s consensus EPS estimate for the upcoming report has changed -18.7% over the past month to -$0.92. Compared to the company’s year-ago EPS, this represents a change of +68.4%. Viridian Therapeutics, Inc. currently boasts a Zacks Rank of #4 (Sell).
Just Released: Zacks Top 10 Stocks for 2022
In addition to the investment ideas discussed above, would you like to know about our 10 top buy-and-hold tickers for the entirety of 2022?
Last year’s 2021
Zacks Top 10 Stocks
portfolio returned gains as high as +147.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys
Access Zacks Top 10 Stocks for 2022 today >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report